Clinical Trial Detail

NCT ID NCT03473730
Title Daratumumab in Patients With Metastatic Renal Cell Carcinoma (MRCC) or Muscle Invasive Bladder Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

renal cell carcinoma

bladder urothelial carcinoma

Therapies

Daratumumab

Age Groups: adult senior

No variant requirements are available.